Efficacy of Molecular Targeting of Cancer Stem Cells in the Treatment and Eradication of Experimentally Induced Triple-Negative Breast Cancer

Background: Triple-negative breast cancer (TNBC) is a destructive form of breast malignancy that deficiencies the opportunities of targeted therapeutics. Developing evidence proposes that breast cancer stem cells (BCSCs), considered the main reason for poor prognosis as they induce resistance, metastasis, and relapse. Aim of the Study: This study aims at examining the efficacy of Doxorubicin, Cyclophosphamide, Salinomycin, Digoxin, and Nano-silica encapsulated copra venom in eradicating BCSCs and managing TNBC. Methods: We performed our study using the TNBCs cell line (MDA-MB-231). Our study involved 5 groups with 5 different interventions; Untreated cells, cells treated by Doxorubicin 3.5 µM only, cells treated by a combination of Salinomycin 15 µM and Doxorubicin 3.5 µM, cells treated by a combination of Digoxin 120 nM and 1 mM Cyclophosphamide and cells treated by a combination of (Naja Haje) venom 3.5 µM and Salinomycin 15 µM. Results: Outcomes of our study demonstrated that the involved therapeutics inhibited the growth of the MDA-MB-231 cell line in a significant way by different efficacies and potencies. Cells treated with the combination of doxorubicin and salinomycin were significantly inhibited at a higher level than those treated with doxorubicin only Digoxin and Cyclophosphamide combination exhibited a lower efficacy than the previous combination in inhibiting the growth of cancer cells. Naja haje venom and Salinomycin combination showed the most significant inhibition of MDA-MB-231 cell line growth. Conclusion: The current study confirms the potency of these novel approaches in the management and the eradication of triple-negative breast cancer.